In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro.

Lozic M, Stambolija V, Krezic I, Dugandzic A, Zivanovic-Posilovic G, Gojkovic S, Kovacevic J, Vrdoljak L, Mirkovic I, Kokot A, Petrovic A, Pavlov KH and 5 more

Show all authors

Drmic D, Suran J, Blagaic AB, Seiwerth S, Sikiric P

Emergency medicine international27 May 2020Cited by 24 (Europe PMC)

PMID32566305PMCIDPMC7273470DOI10.1155/2020/6805354PepBankPUB-32566305

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

Recently, the pentadecapeptide BPC 157-induced counteraction of bupivacaine cardiotoxicity has been reported. Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation. BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before. The BPC 157/NO-system relationship was verified with NO-agents, the NOS-blocker L-NAME and the NOS-substrate L-arginine, given alone and/or together, in axillary and spinal intrathecal blocks. BPC 157 applied immediately after lidocaine or 5 min before the application of lidocaine considerably ameliorated plantar presentation. BPC 157 medication considerably counteracted lidocaine-induced limb function failure; L-NAME was counteracted; L-arginine exhibited counteraction when given immediately after lidocaine, but prolongation was seen when given later. Given together, prophylactically or therapeutically, L-NAME and L-arginine (L-NAME + L-arginine) counteracted the other's response. BPC 157 maintained its original response when given together with L-NAME or L-arginine. When BPC 157 was given together with L-NAME and L-arginine, its original response reappeared. BPC 157 antagonised the lidocaine-induced bradycardia and eliminated tonic-clonic convulsions. Also, BPC 157 counteracted the lidocaine-induced depolarisation of HEK293 cells. Thus, BPC 157 has antidote activity in its own right against lidocaine and local anesthetics.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats given intraplantar lidocaine, BPC‑157 applied immediately after, or 5 min before, lidocaine considerably ameliorated plantar presentation.
In plain wordsIn rats given a local anesthetic, BPC‑157 considerably improved the paw response when given right after or just before.
Peptide
BPC-157
Outcome
IncreasePlantar presentation after lidocaine
Study
ratn: not reported in source
Lidocaine-induced local anesthesia, arrhythmia and convulsion models
Comparator
Lidocaine without BPC 157
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · intraplantar, intraperitoneal or intragastricAs given in this study (rat).
Source sentences
Summary
BPC 157 applied immediately after lidocaine or 5 min before the application of lidocaine considerably ameliorated plantar presentation.
2 context sentences(design, population, supporting numbers)
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with lidocaine-induced axillary and spinal blocks, BPC‑157 considerably counteracted limb function failure.
In plain wordsIn rats given a local anesthetic block, BPC‑157 considerably counteracted loss of limb function.
Peptide
BPC-157
Outcome
DecreaseLidocaine-induced limb function failure
Study
ratn: not reported in source
Lidocaine-induced local anesthesia, arrhythmia and convulsion models
Comparator
Lidocaine without BPC 157
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · intraplantar, intraperitoneal or intragastricAs given in this study (rat).
Source sentences
Summary
BPC 157 medication considerably counteracted lidocaine-induced limb function failure
2 context sentences(design, population, supporting numbers)
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats given lidocaine, BPC‑157 antagonised lidocaine-induced bradycardia.
In plain wordsIn rats given a local anesthetic, BPC‑157 worked against the slowed heart rate it caused.
Peptide
BPC-157
Outcome
DecreaseLidocaine-induced bradycardia
Study
ratn: not reported in source
Lidocaine-induced local anesthesia, arrhythmia and convulsion models
Comparator
Lidocaine without BPC 157
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intraplantar, intraperitoneal or intragastricAs given in this study (rat).
Source sentences
Summary
BPC 157 antagonised the lidocaine-induced bradycardia and eliminated tonic-clonic convulsions.
2 context sentences(design, population, supporting numbers)
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats given lidocaine, BPC‑157 eliminated tonic-clonic convulsions.
In plain wordsIn rats given a local anesthetic, BPC‑157 eliminated seizures caused by it.
Peptide
BPC-157
Outcome
DecreaseLidocaine-induced tonic-clonic convulsions
Study
ratn: not reported in source
Lidocaine-induced local anesthesia, arrhythmia and convulsion models
Comparator
Lidocaine without BPC 157
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intraplantar, intraperitoneal or intragastricAs given in this study (rat).
Source sentences
Summary
and eliminated tonic-clonic convulsions.
2 context sentences(design, population, supporting numbers)
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630504
05AnimalAnimal study (in vivo)Mechanism
In rats given lidocaine, BPC‑157 kept its original response in the presence of the NO-agents L-NAME or L-arginine.
In plain wordsIn rats given a local anesthetic, BPC‑157 kept its effect in the presence of two nitric oxide drugs.
Peptide
BPC-157
Outcome
No significant changeBPC 157 response with L-NAME and L-arginine
Study
ratn: not reported in source
Lidocaine-induced local anesthesia, arrhythmia and convulsion models
Comparator
BPC 157 given without NO-agents
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · intraplantar, intraperitoneal or intragastricAs given in this study (rat).
Source sentences
Summary
The BPC 157/NO-system relationship was verified with NO-agents, the NOS-blocker L-NAME and the NOS-substrate L-arginine, given alone and/or together, in axillary and spinal intrathecal blocks.
3 context sentences(design, population, supporting numbers)
Summary · context
BPC 157 maintained its original response when given together with L-NAME or L-arginine.
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630505
06LabIn vitro (cells)Activity measurement
In HEK293 cells, BPC‑157 counteracted lidocaine-induced depolarisation.
In plain wordsIn lab cells, BPC‑157 counteracted the electrical change caused by lidocaine.
Peptide
BPC-157
Outcome
DecreaseLidocaine-induced HEK293 cell depolarisation
Study
n: not reported in source
HEK293 cells
Comparator
Lidocaine without BPC 157
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Also, BPC 157 counteracted the lidocaine-induced depolarisation of HEK293 cells.
2 context sentences(design, population, supporting numbers)
Summary · context
Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation.
Summary · context
BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before.
Show in the study text Report a problemFND-3256630506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.